IBDEI0W4 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32312,0)
 ;;=C83.79^^119^1564^31
 ;;^UTILITY(U,$J,358.3,32312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32312,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32312,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,32312,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,32313,0)
 ;;=C83.70^^119^1564^32
 ;;^UTILITY(U,$J,358.3,32313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32313,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,32313,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,32313,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,32314,0)
 ;;=D09.0^^119^1564^39
 ;;^UTILITY(U,$J,358.3,32314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32314,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,32314,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,32314,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,32315,0)
 ;;=D06.9^^119^1564^40
 ;;^UTILITY(U,$J,358.3,32315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32315,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,32315,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,32315,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,32316,0)
 ;;=D06.0^^119^1564^42
 ;;^UTILITY(U,$J,358.3,32316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32316,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,32316,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,32316,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,32317,0)
 ;;=D06.1^^119^1564^43
 ;;^UTILITY(U,$J,358.3,32317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32317,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,32317,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,32317,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,32318,0)
 ;;=D06.7^^119^1564^41
 ;;^UTILITY(U,$J,358.3,32318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32318,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,32318,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,32318,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,32319,0)
 ;;=D04.9^^119^1564^44
 ;;^UTILITY(U,$J,358.3,32319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32319,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,32319,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,32319,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,32320,0)
 ;;=C91.11^^119^1564^47
 ;;^UTILITY(U,$J,358.3,32320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32320,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,32320,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,32320,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,32321,0)
 ;;=C91.10^^119^1564^48
 ;;^UTILITY(U,$J,358.3,32321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32321,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,32321,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,32321,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,32322,0)
 ;;=C92.11^^119^1564^49
 ;;^UTILITY(U,$J,358.3,32322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32322,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,32322,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,32322,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,32323,0)
 ;;=C92.10^^119^1564^50
 ;;^UTILITY(U,$J,358.3,32323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32323,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,32323,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,32323,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,32324,0)
 ;;=D47.1^^119^1564^51
 ;;^UTILITY(U,$J,358.3,32324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32324,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,32324,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,32324,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,32325,0)
 ;;=C82.69^^119^1564^52
 ;;^UTILITY(U,$J,358.3,32325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32325,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32325,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,32325,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,32326,0)
 ;;=C82.60^^119^1564^53
 ;;^UTILITY(U,$J,358.3,32326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32326,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,32326,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,32326,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,32327,0)
 ;;=D56.2^^119^1564^54
 ;;^UTILITY(U,$J,358.3,32327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32327,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,32327,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,32327,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,32328,0)
 ;;=D75.9^^119^1564^55
 ;;^UTILITY(U,$J,358.3,32328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32328,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,32328,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,32328,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,32329,0)
 ;;=D59.0^^119^1564^58
 ;;^UTILITY(U,$J,358.3,32329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32329,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,32329,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,32329,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,32330,0)
 ;;=D59.2^^119^1564^59
 ;;^UTILITY(U,$J,358.3,32330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32330,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,32330,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,32330,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,32331,0)
 ;;=R59.9^^119^1564^62
 ;;^UTILITY(U,$J,358.3,32331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32331,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,32331,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,32331,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,32332,0)
 ;;=D47.3^^119^1564^63
 ;;^UTILITY(U,$J,358.3,32332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32332,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,32332,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,32332,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,32333,0)
 ;;=C82.09^^119^1564^64
 ;;^UTILITY(U,$J,358.3,32333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32333,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32333,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,32333,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,32334,0)
 ;;=C82.00^^119^1564^65
 ;;^UTILITY(U,$J,358.3,32334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32334,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,32334,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,32334,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,32335,0)
 ;;=C82.19^^119^1564^66
 ;;^UTILITY(U,$J,358.3,32335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32335,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32335,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,32335,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,32336,0)
 ;;=C82.10^^119^1564^67
 ;;^UTILITY(U,$J,358.3,32336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32336,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,32336,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,32336,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,32337,0)
 ;;=C82.29^^119^1564^68
 ;;^UTILITY(U,$J,358.3,32337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32337,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,32337,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,32337,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,32338,0)
 ;;=C82.20^^119^1564^69
 ;;^UTILITY(U,$J,358.3,32338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32338,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,32338,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,32338,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,32339,0)
 ;;=C82.39^^119^1564^70
